A Study of Adrenal Incidentaloma-Related Hormonal Assays After First Integration of the Diagnosis Within Primary Healthcare

Background: Adrenal incidentalomas are detected in various medical and surgical healthcare departments, including primary healthcare. One up to three out of ten individuals confirmed with nonfunctioning adrenal incidentalomas (NFAs) actually present a mild autonomous cortisol secretion (MACS), which...

Full description

Saved in:
Bibliographic Details
Main Authors: Oana-Claudia Sima, Mihai Costachescu, Ana Valea, Mihaela Stanciu, Ioana Codruta Lebada, Tiberiu Vasile Ioan Nistor, Mihai-Lucian Ciobica, Claudiu Nistor, Mara Carsote
Format: Article
Language:English
Published: MDPI AG 2025-05-01
Series:Diseases
Subjects:
Online Access:https://www.mdpi.com/2079-9721/13/6/169
Tags: Add Tag
No Tags, Be the first to tag this record!
_version_ 1850156891928264704
author Oana-Claudia Sima
Mihai Costachescu
Ana Valea
Mihaela Stanciu
Ioana Codruta Lebada
Tiberiu Vasile Ioan Nistor
Mihai-Lucian Ciobica
Claudiu Nistor
Mara Carsote
author_facet Oana-Claudia Sima
Mihai Costachescu
Ana Valea
Mihaela Stanciu
Ioana Codruta Lebada
Tiberiu Vasile Ioan Nistor
Mihai-Lucian Ciobica
Claudiu Nistor
Mara Carsote
author_sort Oana-Claudia Sima
collection DOAJ
description Background: Adrenal incidentalomas are detected in various medical and surgical healthcare departments, including primary healthcare. One up to three out of ten individuals confirmed with nonfunctioning adrenal incidentalomas (NFAs) actually present a mild autonomous cortisol secretion (MACS), which is distinct from Cushing’s syndrome. Objective: We aimed to assess the cortisol secretion in newly detected adrenal incidentalomas in patients who were referred by their primary healthcare physician upon accidental detection of an adrenal tumor at abdominal computed tomography (CT) scan that was performed for unrelated (non-endocrine) purposes. Methods: This retrospective study included adults diagnosed with an adrenal incidentaloma via CT during the previous 3 months. Inclusion criteria: age ≥ 40 years (y). A triple stratification of exclusion criteria involved: (1) Clinical aspects and medical records such as active malignancies or malignancies under surveillance protocols, subjects under exogenous glucocorticoid exposure (current or during the previous year), or suggestive endocrine phenotypes for any hormonal ailment; (2) Radiological appearance of suspected/confirmed (primary or secondary) adrenal malignancy, adrenal cysts, or myelolipomas; (3) Endocrine assays consistent with active endocrine tumors. Protocol of assessment included baseline ACTH, morning plasma cortisol (C-B), cortisol at 6 p.m. (C-6 pm), and after 1 mg dexamethasone suppression testing (C-1 mg-DST), 24-h urinary free cortisol (UFC), and a second opinion for all CT scans. MACS were defined based on C-1 mg-DST ≥ 1.8 and <5 µg/dL (non-MACS: C-1 mg-DST < 1.8 µg/dL). Results: The cohort (N = 60, 78.33% female; 60.72 ± 10.62 y) associated high blood pressure (HBP) in 66.67%, respectively, type 2 diabetes (T2D) in 28.37% of the patients. Females were statistically significantly older than males (62.40 ± 10.47 vs. 54.62 ± 9.11 y, <i>p</i> = 0.018), while subjects with unilateral vs. bilateral tumors (affecting 26.67% of the individuals) and those with MACS-positive vs. MACS-negative profile had a similar age. Body mass index (BMI) was similar between patients with unilateral vs. bilateral incidentalomas, regardless of MACS. Patients were divided into five age groups (decades); most of them were found between 60 and 69 years (40%). Left-gland involvement was found in 43.33% of all cases. The mean largest tumor diameter was 26.08 ± 8.78 mm. The highest rate of bilateral tumors was 46.67% in the 50–59 y decade. The rate of unilateral/bilateral and tumor diameters was similar in females vs. males. The MACS-positive rate was similar in females vs. males (23.40% vs. 23.08%). A statistically significant negative correlation (N = 60) was found between BMI and C-B (r = −0.193, <i>p</i> = 0.03) and BMI and UFC (r = −0.185, <i>p</i> = 0.038), and a positive correlation was found between C-B and C-6 pm (r = 0.32, <i>p</i> < 0.001), C-B and UFC (r = 0.226, <i>p</i> = 0.011), and C-6 pm and C-1 mg-DST (r = 0.229, <i>p</i> = 0.010), and the largest tumor diameter and C-1 mg-DST (r = 0.241, <i>p</i> = 0.007). Conclusions: Adrenal incidentalomas belong to a complex scenario of detection in the modern medical era, requiring a multidisciplinary collaboration since the patients might be initially detected in different departments (as seen in the current study) and then referred to primary healthcare for further decision. In these consecutive patients, we found a higher female prevalence, a MACS rate of 23.33%, regardless of uni/bilateral involvement or gender distribution, and a relatively high rate (than expected from general data) of bilateral involvement of 26.67%. The MACS-positive profile adds to the disease burden and might require additional assessments during follow-up and a protocol of surveillance, including a tailored decision of tumor removal. The identification of an adrenal incidentaloma at CT and its hormonal characterization needs to be integrated into the panel of various chronic disorders of one patient. The collaboration between endocrinologists and primary healthcare physicians might improve the overall long-term outcomes.
format Article
id doaj-art-5297825d7ead49faa9e24b591d5e38ce
institution OA Journals
issn 2079-9721
language English
publishDate 2025-05-01
publisher MDPI AG
record_format Article
series Diseases
spelling doaj-art-5297825d7ead49faa9e24b591d5e38ce2025-08-20T02:24:21ZengMDPI AGDiseases2079-97212025-05-0113616910.3390/diseases13060169A Study of Adrenal Incidentaloma-Related Hormonal Assays After First Integration of the Diagnosis Within Primary HealthcareOana-Claudia Sima0Mihai Costachescu1Ana Valea2Mihaela Stanciu3Ioana Codruta Lebada4Tiberiu Vasile Ioan Nistor5Mihai-Lucian Ciobica6Claudiu Nistor7Mara Carsote8PhD Doctoral School of “Carol Davila” University of Medicine and Pharmacy, 010825 Bucharest, RomaniaDepartment of Radiology and Medical Imaging, Fundeni Clinical Institute, 022328 Bucharest, RomaniaDepartment of Endocrinology, “Iuliu Hatieganu” University of Medicine and Pharmacy, 400012 Cluj-Napoca, RomaniaDepartment of Endocrinology, “Lucian Blaga” University of Sibiu, 550024 Sibiu, RomaniaDepartment of Endocrinology, “Lucian Blaga” University of Sibiu, 550024 Sibiu, RomaniaMedical Biochemistry Discipline, “Iuliu Hatieganu” University of Medicine and Pharmacy, 400347 Cluj-Napoca, RomaniaDepartment of Internal Medicine and Gastroenterology, “Carol Davila” University of Medicine and Pharmacy, 020021 Bucharest, RomaniaDepartment 4—Cardio-Thoracic Pathology, Thoracic Surgery II Discipline, “Carol Davila” University of Medicine and Pharmacy, 0505474 Bucharest, RomaniaDepartment of Endocrinology, “Carol Davila” University of Medicine and Pharmacy, 020021 Bucharest, RomaniaBackground: Adrenal incidentalomas are detected in various medical and surgical healthcare departments, including primary healthcare. One up to three out of ten individuals confirmed with nonfunctioning adrenal incidentalomas (NFAs) actually present a mild autonomous cortisol secretion (MACS), which is distinct from Cushing’s syndrome. Objective: We aimed to assess the cortisol secretion in newly detected adrenal incidentalomas in patients who were referred by their primary healthcare physician upon accidental detection of an adrenal tumor at abdominal computed tomography (CT) scan that was performed for unrelated (non-endocrine) purposes. Methods: This retrospective study included adults diagnosed with an adrenal incidentaloma via CT during the previous 3 months. Inclusion criteria: age ≥ 40 years (y). A triple stratification of exclusion criteria involved: (1) Clinical aspects and medical records such as active malignancies or malignancies under surveillance protocols, subjects under exogenous glucocorticoid exposure (current or during the previous year), or suggestive endocrine phenotypes for any hormonal ailment; (2) Radiological appearance of suspected/confirmed (primary or secondary) adrenal malignancy, adrenal cysts, or myelolipomas; (3) Endocrine assays consistent with active endocrine tumors. Protocol of assessment included baseline ACTH, morning plasma cortisol (C-B), cortisol at 6 p.m. (C-6 pm), and after 1 mg dexamethasone suppression testing (C-1 mg-DST), 24-h urinary free cortisol (UFC), and a second opinion for all CT scans. MACS were defined based on C-1 mg-DST ≥ 1.8 and <5 µg/dL (non-MACS: C-1 mg-DST < 1.8 µg/dL). Results: The cohort (N = 60, 78.33% female; 60.72 ± 10.62 y) associated high blood pressure (HBP) in 66.67%, respectively, type 2 diabetes (T2D) in 28.37% of the patients. Females were statistically significantly older than males (62.40 ± 10.47 vs. 54.62 ± 9.11 y, <i>p</i> = 0.018), while subjects with unilateral vs. bilateral tumors (affecting 26.67% of the individuals) and those with MACS-positive vs. MACS-negative profile had a similar age. Body mass index (BMI) was similar between patients with unilateral vs. bilateral incidentalomas, regardless of MACS. Patients were divided into five age groups (decades); most of them were found between 60 and 69 years (40%). Left-gland involvement was found in 43.33% of all cases. The mean largest tumor diameter was 26.08 ± 8.78 mm. The highest rate of bilateral tumors was 46.67% in the 50–59 y decade. The rate of unilateral/bilateral and tumor diameters was similar in females vs. males. The MACS-positive rate was similar in females vs. males (23.40% vs. 23.08%). A statistically significant negative correlation (N = 60) was found between BMI and C-B (r = −0.193, <i>p</i> = 0.03) and BMI and UFC (r = −0.185, <i>p</i> = 0.038), and a positive correlation was found between C-B and C-6 pm (r = 0.32, <i>p</i> < 0.001), C-B and UFC (r = 0.226, <i>p</i> = 0.011), and C-6 pm and C-1 mg-DST (r = 0.229, <i>p</i> = 0.010), and the largest tumor diameter and C-1 mg-DST (r = 0.241, <i>p</i> = 0.007). Conclusions: Adrenal incidentalomas belong to a complex scenario of detection in the modern medical era, requiring a multidisciplinary collaboration since the patients might be initially detected in different departments (as seen in the current study) and then referred to primary healthcare for further decision. In these consecutive patients, we found a higher female prevalence, a MACS rate of 23.33%, regardless of uni/bilateral involvement or gender distribution, and a relatively high rate (than expected from general data) of bilateral involvement of 26.67%. The MACS-positive profile adds to the disease burden and might require additional assessments during follow-up and a protocol of surveillance, including a tailored decision of tumor removal. The identification of an adrenal incidentaloma at CT and its hormonal characterization needs to be integrated into the panel of various chronic disorders of one patient. The collaboration between endocrinologists and primary healthcare physicians might improve the overall long-term outcomes.https://www.mdpi.com/2079-9721/13/6/169primary healthadrenaltumorimaginghormoneendocrine
spellingShingle Oana-Claudia Sima
Mihai Costachescu
Ana Valea
Mihaela Stanciu
Ioana Codruta Lebada
Tiberiu Vasile Ioan Nistor
Mihai-Lucian Ciobica
Claudiu Nistor
Mara Carsote
A Study of Adrenal Incidentaloma-Related Hormonal Assays After First Integration of the Diagnosis Within Primary Healthcare
Diseases
primary health
adrenal
tumor
imaging
hormone
endocrine
title A Study of Adrenal Incidentaloma-Related Hormonal Assays After First Integration of the Diagnosis Within Primary Healthcare
title_full A Study of Adrenal Incidentaloma-Related Hormonal Assays After First Integration of the Diagnosis Within Primary Healthcare
title_fullStr A Study of Adrenal Incidentaloma-Related Hormonal Assays After First Integration of the Diagnosis Within Primary Healthcare
title_full_unstemmed A Study of Adrenal Incidentaloma-Related Hormonal Assays After First Integration of the Diagnosis Within Primary Healthcare
title_short A Study of Adrenal Incidentaloma-Related Hormonal Assays After First Integration of the Diagnosis Within Primary Healthcare
title_sort study of adrenal incidentaloma related hormonal assays after first integration of the diagnosis within primary healthcare
topic primary health
adrenal
tumor
imaging
hormone
endocrine
url https://www.mdpi.com/2079-9721/13/6/169
work_keys_str_mv AT oanaclaudiasima astudyofadrenalincidentalomarelatedhormonalassaysafterfirstintegrationofthediagnosiswithinprimaryhealthcare
AT mihaicostachescu astudyofadrenalincidentalomarelatedhormonalassaysafterfirstintegrationofthediagnosiswithinprimaryhealthcare
AT anavalea astudyofadrenalincidentalomarelatedhormonalassaysafterfirstintegrationofthediagnosiswithinprimaryhealthcare
AT mihaelastanciu astudyofadrenalincidentalomarelatedhormonalassaysafterfirstintegrationofthediagnosiswithinprimaryhealthcare
AT ioanacodrutalebada astudyofadrenalincidentalomarelatedhormonalassaysafterfirstintegrationofthediagnosiswithinprimaryhealthcare
AT tiberiuvasileioannistor astudyofadrenalincidentalomarelatedhormonalassaysafterfirstintegrationofthediagnosiswithinprimaryhealthcare
AT mihailucianciobica astudyofadrenalincidentalomarelatedhormonalassaysafterfirstintegrationofthediagnosiswithinprimaryhealthcare
AT claudiunistor astudyofadrenalincidentalomarelatedhormonalassaysafterfirstintegrationofthediagnosiswithinprimaryhealthcare
AT maracarsote astudyofadrenalincidentalomarelatedhormonalassaysafterfirstintegrationofthediagnosiswithinprimaryhealthcare
AT oanaclaudiasima studyofadrenalincidentalomarelatedhormonalassaysafterfirstintegrationofthediagnosiswithinprimaryhealthcare
AT mihaicostachescu studyofadrenalincidentalomarelatedhormonalassaysafterfirstintegrationofthediagnosiswithinprimaryhealthcare
AT anavalea studyofadrenalincidentalomarelatedhormonalassaysafterfirstintegrationofthediagnosiswithinprimaryhealthcare
AT mihaelastanciu studyofadrenalincidentalomarelatedhormonalassaysafterfirstintegrationofthediagnosiswithinprimaryhealthcare
AT ioanacodrutalebada studyofadrenalincidentalomarelatedhormonalassaysafterfirstintegrationofthediagnosiswithinprimaryhealthcare
AT tiberiuvasileioannistor studyofadrenalincidentalomarelatedhormonalassaysafterfirstintegrationofthediagnosiswithinprimaryhealthcare
AT mihailucianciobica studyofadrenalincidentalomarelatedhormonalassaysafterfirstintegrationofthediagnosiswithinprimaryhealthcare
AT claudiunistor studyofadrenalincidentalomarelatedhormonalassaysafterfirstintegrationofthediagnosiswithinprimaryhealthcare
AT maracarsote studyofadrenalincidentalomarelatedhormonalassaysafterfirstintegrationofthediagnosiswithinprimaryhealthcare